Famciclovir/Penciclovir

Advances in Experimental Medicine and Biology

Volumn 458, Issue , 1999, Pages 135-147

  Sacks, S L ^a   Wilson, B ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 DEOXYPENCICLOVIR; 6 DEOXYPENCICLOVIR DIPROPIONATE; ACICLOVIR; DRUG METABOLITE; FAMCICLOVIR; PENCICLOVIR; PRODRUG;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CROSS RESISTANCE; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; GENITAL HERPES; HEADACHE; HERPES LABIALIS; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; NAUSEA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RECURRENT INFECTION;

HERPES; HERPES ZOSTER; HERPESVIRIDAE;

EID: 0033281796     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4743-3_13     Document Type: Conference Paper

References (53)

1. Double-blind, randomised, placebo-controlled, lesional, clinic-initiated treatment of culture positive recurrent genital herpes with intravenous penciclovir: Clinical benefits of rapid-onset antiviral activity
2. Efficacy and safety of penciclovir (PCV) for the treatment of HSV infections in immunocompromised (IC) patients
3. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial
4. The mode of action of penciclovir
5. Famciclovir and penciclovir: The mode of action of famciclovir including its conversion to penciclovir
6. Selection of an Oral Prodrug (BRL 42810; Famciclovir) for the Antiherpesvirus Agent BRL 39123 [9-(4-Hydroxy-3-Hydroxymethylbut-1-yl)Guanine; Penciclovir]
7. Pharmacokinetics of famciclovir in man
8. Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects
9. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL+39123) in cell culture
10. New antivirals with activity against varicella-zoster virus
11. Assay of famciclovir and its metabolites, including the antiherpes agent penciclovir, in plasma and urine of rats, dog, and man
12. Pharmacokinetics of the acyclovir pro-drug valacyclovir after escalating single and multiple-dose administration to normal volunteers
13. Pharmacokinetics of penciclovir in healthy elderly subjects following a single oral administration of 750 mg famciclovir
14. Famciclovir: Review of clinical efficacy and safety
15. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment
16. Pharmacokinetics of famciclovir in subjects with chronic hepatic disease
17. A further study of the effect of food on the bioavailability and pharmacokinetics of penciclovir after oral administration of famciclovir
18. Effect of food on bioavailability and pharmacokinetics of penciclovir, a novel antiherpes agent, following oral administration of the pro-drug, famciclovir
19. Penciclovir pharmacokinetics in fed and fasted subjects following oral famciclovir in relation to in-vitro antiviral activity
20. Drug interaction studies and safety of famciclovir in healthy volunteers
21. Resistance of herpesviruses to antiviral drugs
22. Penciclovir: A review of its spectrum of activity, selectivity and cross-resistance pattern
23. Famciclovir, a new oral antiherpes drug: Results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immune competent patients
24. Famciclovir for the treatment of acute herpes zoster: Effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial
25. Assessment of pain in herpes zoster: Lessons learned from antiviral trials
26. Postherpetic neuralgia: Impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients
27. Economic evaluation of antiviral therapy for the treatment of herpes zoster in immunocompetent adults
28. Early, clinic-initiated treatment of recurrent genital herpes using famciclovir: Results of a Canadian, multicenter study
29. Patient-initiated, twice daily oral famciclovir for early recurrent genital herpes reduces the onset and duration of viral shedding, the duration of lesions and their components and symptoms: A Canadian, multicenter, randomized, placebo-controlled, dose-ranging trial
30. Episodic clinic- and patient-initiated famciclovir (FCV) for recurrent genital herpes (GHSV): A combined analysis
31. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial
32. Oral famciclovir for the suppression of recurrent genital herpes
33. Famciclovir for suppression of asymptomatic and symptomatic recurrent genital herpes shedding: A randomized, double-blind double-dummy, parallel-group, placebo-controlled trial
34. Famciclovir suppression of asymptomatic HSV shedding in recurrent genital herpes
35. Effect of long-term famciclovir treatment on sperm parameters in patients with recurrent genital herpes
36. Oral famciclovir (FCV) a new antiherpes agent: Comparative study with acyclovir in clinic initiated treatment of first episode genital herpes (FGH)
37. Treatment of first episode genital herpes with famciclovir
38. Famciclovir in the management of first-episode genital herpes
39. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency
40. Famciclovir and valaciclovir differ in the prevention of herpes simplex virus type I latency in mice: A quantitative study
41. Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model
42. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type I in a murine immunosuppression model
43. Current status of herpes simplex labialis
44. Treatment of herpes simplex labialis
45. Dermal irritancy potential of penciclovir cream compared with acyclovir 5% cream in health volunteers
46. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial
47. Penciclovir cream for recurrent herpes simplex labialis
48. Acyclovir prevents reactivation of herpes simplex labialis in skiers
49. Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial
50. Efficacy and safety of famciclovir for the treatment of HSV infection in HIV+ patients. 6th Canadian Conference on HIV/AIDS Research
51. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex vires reactivation in HIV-infected persons